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ABBREVIATIONS: 
 
ABL – ablation/mapping catheter  
Ado – adenosine  
AF – atrial fibrillation 
ATs – atrial tachycardia  
AV – atrioventricular  
BSA  – body surface area 
CFAE – complex fractionated atrial electrograms 
CMC – circular mapping catheter 
CS – coronary sinus 
CTI – cavo-tricuspid isthmus 
DCCV – direct cardioversion 
DF – dominant frequency 
DF – dominant frequency 
DiFi – dissociated firing 
EAM – electro anatomical mapping 
ERP – effective refractory period 
ICE – intracardiac echocardiography  
IRAF – immediate recurrence of atrial fibrillation 
IRAF – immediate recurrence of atrial fibrillation 
Iso – isoproterenol 
LA – left atrium 
LAP – left atrial pressure 
LAV – left atrial volum 
LAVI – left atrial volum indexed 
LIPV – left inferior pulmonary vein 
LSPV – left superior pulmonary vein 
LVEF – left ventricular ejection fraction 
MA – mitral annulus 
PAF – paroxysmal atrial fibrillation 
PALS – peak atrial longitudinal strain 
PPI – post pacing interval 
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PVI – pulmonary vein isolation 
PVs – pulmonary veins  
RIPV – right inferior pulmonary vein 
RSPV – right superior pulmonary vein 
SI – stiffness index 
TCL – tachycardia cycle length 
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INTRODUCTION 
 
Atrial fibrillation (AF) is an arrhythmia of increasing prevalence. Since the identification of 
trigger activity in the pulmonary vein (PVs) by Haissaguerre et al, (1) catheter ablation of 
atrial fibrillation (AF) has become an established therapeutic modality for the treatment of 
patients with AF. Over the last decades, pulmonary vein isolation (PVI) has become the 
mainstay of ablation treatment of atrial fibrillation. Thereby, durable PV isolation (PVI) is a 
highly effective therapy when PV arrhythmogenicity is responsible for PAF. However, when 
other pathophysiologic mechanisms are involved, the effectiveness of PVI may be limited (2).  
Published data in the literature suggest that success rates following ablation of AF are 
relatively favorable (50-70%) (3, 4, 5). The AF population is very heterogeneous, with respect 
to duration and type of arrhythmia, comorbidities etc, and ablation results may depend on 
different definitions of success, follow-up methods, type of AF and ablation strategies. The 
success of catheter ablation may also depend on technical aspects of the procedure and the 
frequency and intensity of arrhythmia monitoring.  
Regardless of the ablation techniques used, ablation of AF may result in regular atrial 
tachycardias (ATs) or flutter, which is one of the most important proarrhythmic complications 
after left atrial (LA) ablation. Atrial tachycardias that occur after AF ablation can cause even 
more severe symptoms than those from the original arrhythmia prior to the index ablation 
procedure since they are often incessant and associated with rapid ventricular response, which 
is difficult to control using antiarrhythmic medications. 
After achieving PVI, dissociated firing (DiFi) from PVs is frequently observed (6). The 
capability of PVs to generate an isolated ectopic rhythm may signify their arrhythmic 
potential and therefore predict a higher success (7). On the other hand, the presence of DiFi 
may be related to better quality of PVI, farther away from PV ostia, also suggesting improved 
outcome (8). Whether spontaneous electrical activity of isolated PVs is related to their 
arrhythmogenicity or only an epiphenomenon and whether observing DiFi after PVI has 
prognostic significance remain unclear. 
Arrhythmogenic ectopy triggering AF can be identified during the electrophysiology study if 
spontaneously occurring or can be induced by drug challenge. Due to the spurious nature of 
spontaneous triggers and the laboriousness of AF provocation, empirical isolation of all PVs 
has become the standard in AF ablation, despite the fact that selective isolation of only the 
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triggering PV can achieve similar success in selected patients (9). Even if total PV isolation is 
pursued as a first step, identification of non-PV triggers gains importance when AF occurs 
despite isolated PVs (10, 11). The role of high dose isoproterenol (Iso) infusion to elicit AF 
triggers is well established (12, 13). Besides Iso, adenosine (Ado) or adenosine-triphosphate 
(ATP) is increasingly used for the induction of AF, despite the lack of systematic studies on 
the sensitivity and specificity of these drugs. 
 
 
AIMS 
 
For improving the outcome after AF ablation, we sought to investigate different aspects 
starting with a literature review (success rate, predictors and mechanism of recurrent atrial 
arrhythmias), pathophysiologic mechanism, assessment of the triggering PVs and 
identification of non-PV triggers using different drugs. First, we study the response in 
electrical (mechanoelectrical feedback) and reservoir function to acute pressure elevation in 
the normal human LA and in the LA of patients with AF. Second, we investigate whether 
dissociated firing in isolated PVs implies arrhythmogenicity of the particular PV and 
therefore, a better outcome of PVI. Third, for the identification of AF triggers we compare 
Ado to Iso for the induction of paroxysmal AF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6 
 
LITERATURE REVIEW  
 
To be able to evaluate the very long-term results of atrial fibrillation ablation we conducted a 
systematic literature review of all relevant studies published until March 2015. A 
comprehensive discussion of long-term outcome of catheter ablation including parameters 
like type of AF, ablation strategies, the use of antiarrhythmic drugs after ablation, multiple 
procedures, success definitions, the frequency and intensity of arrhythmia monitoring. We 
have also analyzed our database of patients with paroxysmal and persistent atrial fibrillation 
ablation. 
 
Definition Of Long-Term Follow-Up 
In the 2012 Expert Consensus on catheter ablation of atrial fibrillation, (14) late recurrence of 
AF is defined as a recurrence after 12 months or more after AF ablation and the long-term 
success is defined as freedom from AF following the 3 months blanking period through a 
minimum of 36 months.  
There is also consensus that all patients who undergo catheter ablation of AF should be 
controlled every six months for at least two years. In our review, we defined very long-term 
follow-up to be longer than 3 years after the index procedure. 
 
Impact Of Type Of AF  
Depending on whether patients have paroxysmal (PAF), persistent, or longstanding persistent 
AF, the outcome of ablation procedures differs considerably. A systematic review and meta-
analysis including, mostly retrospective studies published by Ganesan et al (15) demonstrated 
that the single procedure success for PAF was 68.6 % at 1 year, 61.1% at 3 years and 62.3% 
at 5 years.  
After multiple procedures (average 1.45 procedure per patient) 79% of patients were free 
from AF at 5 years follow-up. Comparing patients with persistent and long-standing persistent 
AF after a single procedure the results were less favorable, 50.8% at 1 year, and 41.6% at 3 
years.  
After multiple procedures, the success was definitely more promising in this population, 
77.8% in the long-term, but only few studies reported the outcome of AF ablation after more 
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than 3 years suggesting that we need more data to definitively assess the very long-term 
efficacy of ablation in persistent atrial fibrillation.  
An interesting question concerning the long-term recurrence and efficacy of the ablation 
procedure whether these interventions can prevent progression of the arrhythmia from 
paroxysmal to persistent form. In the study of Takigawa et al (3) during a median follow-up 
of approximately 48 months, AF progressed from paroxysmal to persistent in 1.2 % of 
patients in accordance with previous investigations where the AF progression rate was similar 
(1.5% -3%). (16, 17)  
In contrast, the results of pharmacologic therapy are definitely worse, the reported rates vary 
between 5.5% and 15%/ year (18, 19). These observations suggest that the interventional 
therapy is better than drugs alone for preventing AF progression, which is an important aspect 
of long-term consequences of the arrhythmia. 
 
Impact of Ablation Techniques 
Whereas a consensus has been reached on the suitable approach for ablation of patients with 
paroxysmal AF, (14) no such consensus exists for patients with persistent and long lasting 
persistent AF regarding the optimal technology of treatment.  
Numerous clinical trials demonstrated that the main mechanism of AF recurrence after PVI in 
the paroxysmal population is the resumption of electrical conduction between the veins and 
left atrial muscle. This statement is true for either the short or the long-term recurrences (see 
below). (15, 20) Base upon these observations we should assume that at least in PAF, the 
durability of venous isolation and therefore permanent electrical disconnection plays a crucial 
role in maintaining procedural effectiveness in the long-term.  
Accordingly, any kind of procedural tool or technique which can facilitate the durable 
isolation of pulmonary veins can be useful. An alternative energy source that has been 
developed to overcome some of the disadvantages of radiofrequency ablation is cryoenergy 
using a balloon based technology.  
A comparison (1:1 propensity score match) between cryoballoon and radiofrequency ablation 
showed similar long-term success rates with a recurrence rate of 45 % in both groups after a 
two-year follow-up (21). Neumann et al (22) reported freedom from AF in 74% of patients 
with paroxysmal AF and 42% with persistent AF, but the follow-up time was shorter.  
Cryoablation is a new technology and it is under continuous development, but whether it can 
improve very long-term outcomes has to be investigated in the future. As mentioned earlier, 
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in patients with persistent and longstanding persistent AF the data concerning the outcomes 
are considerably less favorable than for PAF. The wide contrast in PVI success rates between 
paroxysmal and persistent AF suggested that the mechanisms can be substantially different, 
and probably related to electrophysiological and structural remodeling of left atrial substrate.  
Not surprisingly, current approaches designed to target persistent AF are mainly based on 
modification of the atrial substrate, but exhibit remarkable differences, and a widely accepted 
uniform strategy is missing. Different ablation strategies, including the ablation of complex 
fractionated atrial electrograms (CFAEs), (23) linear lesions in the LA, (24) ablation at the 
maximal high dominant frequency spots, (25) rotor ablation (26) have been developed as an 
add-on to PVI to improve the outcome in this group.  
They reported the success rate of other techniques: linear ablation in addition to PVI (11-
74%), posterior wall isolation (42-50%) CFAE ablation (36-68%) or „stepwise” ablation 
approach (38-62%). The integration of repeat procedures and addition of previously 
ineffective antiarrhythmic drugs further improved clinical success. Our approach is wide area 
antral circumferential ablation for paroxysmal and persistent patients as well, with complete 
isolation of PVs, without creating additional lesions in the LA. During the procedures we use 
open irrigation radiofrequency catheters and a combination of EAM and intracardiac 
echocardiography to enhance the anatomical orientation and the monitoring of catheter-tissue 
contact. After a mean of 18 months follow-up time the recurrence rate after single procedure 
was 52% and 61%, after multiple procedures was 19% and 29%, in a paroxysmal and 
persistent cohort respectively (Fig. 1.) 
 
 
Figure 1. Kaplan-Meier curve representing the arrhythmia free survival after single ablation procedure (Panel A) 
and following multiple ablation procedures (Panel B) in patients with paroxysmal (solid lines) vs persistent atrial 
fibrillation (broken lines). Data are originating from the database of Szeged University. 
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Impact of Follow-up Techniques 
Apart from the above-mentioned factors, the varying results reported by those studies could be 
attributed to substantial differences in follow-up methods. During the first year, the majority of 
studies performed clinical examination, electrocardiogram and 24 - hour Holter monitoring or 
event recorders at 3, 6, and 12 months. Beyond the first year, the intensity of follow-up is usually 
reduced to 1 or 2 outpatient visits per year or even based on data from referring clinicians. (27) 
There is a clear positive correlation between the duration and intensity of the follow-up and the 
arrhythmia detection rate. (28) For the short-term follow-up, 7 day Holter and trans telephonic 
monitoring are proven to be effective to detect asymptomatic AF episodes. Piorkowski et al. (28) 
showed that using serial 7-day Holter and trans-telephonic monitoring, the „real” procedural 
success rate decreased from 70% to 50% and 45% respectively.  
The definition of long-term ablation success remains controversial because current post ablation 
rhythm monitoring strategies are based on symptom and/or intermittent ECG recordings and thus 
probably underestimate the real rate of AF recurrences. (29) Continuous monitoring like 
implantable loop recorders are useful tools (30) but to put these devices into an everyday practice 
is limited by cost, patient’s compliance and high burden of false detection. 
 
Predictors And Mechanism Of Recurrence 
As we suggested earlier, the success of catheter ablation may depend on technical aspects of 
the procedure but also on patient related factors. Patients in whom AF recurred, exhibit 
specific clinical characteristics which can be considered as independent predictors of late AF 
recurrence. Some studies reported history of persistent AF as a predictor of very late 
recurrence (15, 31, 32) while other studies found that there was no significant association 
between the AF type and risk of recurrence. (20, 33) The heterogeneity in results across the 
studies can be explained by the heterogeneous definition of AF type and the differences in 
terminology pertaining to „long-term” follow-up.  
The duration of AF history is a very important predictor of AF recurrence, (3) but other studies 
could not find a significant association between AF duration and AF recurrence. (34, 35)  
A possible explanation is that duration of AF does not necessarily correlate with the length of 
the AF episodes and may not reflect the extent of atrial remodeling. (36) Other commonly 
identified predictors of AF recurrence are age > 65 years, left atrial diameter >24mm/m², (36) 
left ventricular systolic dysfunction, heart failure, structural or valvular heart disease, (15) 
hypertension and hyperlipidemia. (20)  
 10 
These observations indicate the role of enhanced vulnerability of left atrial myocardium 
induced by these factors beyond the importance of trigger mechanism. Aggressive medical 
treatment of these conditions and risk factors reduction may improve the efficacy of AF 
ablation. Pathak et al. (37) reported in a recent publication that risk factor management 
according to American Heart Association/American College of Cardiology guidelines 
significantly improved the outcome of AF ablation in terms of AF burden and also generated 
favorable changes in cardiac remodeling.  
The main mechanism of the early recurrence following atrial fibrillation ablation is the 
reconnection of previously isolated pulmonary veins. In contrast, in patients with very late 
recurrence the mechanism is not completely elucidated. Lin et al. (38) found that the majority 
of patients with recurrent AF undergoing a 3rd  or more procedure after a mean follow-up of 
36±22 months (range 12 to 119 months) had reconnected pulmonary veins with triggers 
originating from the culprit PVs. (Fig. 2). However, in 20% of patients, new non-PV triggers 
were identified at the time of 3rd  or 4th  procedure and the majority of non-PV triggers were 
mapped in the right atrium or coronary sinus.  
 
 
Figure 2. Late reconnection of the right inferior pulmonary veins in a 56 years old patient with PAF following 
32 months the index PVI. Single ablation attempt at the level of earliest PV potentials on Lasso, 4-5 bipoles 
(arrow) resulted immediate isolation of the vein. All of the other pulmonary veins were isolated. Surface ECG 
leads I, II, V1 and V6, together with intracardiac recordings from the Lasso catheter (Lasso) placed in the right 
inferior pulmonary vein, and from the proximal to distal coronary sinus bipoles (CS). Tracing is originating from 
the database of Szeged University. 
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One of the most important proarrhythmic complications after LA ablation is regular atrial 
tachycardia or flutter. Depending on the method and extent of left atrial ablation and on the 
electrophysiological properties of underlying LA substrate, the reported incidence of late ATs 
is variable. The less is the harm caused in the LA, the lower is the incidence of late AT.  
Consequently using the „initial” approach of segmental electrical PVI, which is limited to the 
ostia of pulmonary veins (PV) the occurrence was found to be relatively low, between 1% and 
2.9% (39-42). Gaita et al. (43) concluded that in persistent atrial fibrillation, pulmonary vein 
isolation plus left atrial linear lesion is superior to pulmonary vein isolation alone in 
maintaining sinus rhythm. However, when PV ablation was achieved by placing circular 
lesions around the veins in the LA antrum, without targeting complete isolation of pulmonary 
veins, and creating additional lines in LA (e.g. mitral isthmus, and/or roof, or posterior lines) 
the incidence of ATs dramatically increased to even 10-fold higher, ranging from 10% to 24% 
(44, 45).  
Sawhney et al. (46) randomized a series of patients with structurally normal hearts and 
paroxysmal AF to PVI with electrical isolation versus circular PV ablation plus additional 
lines with confirmation of completeness of circular and linear lines. After isolation of PVs 
without additional lines there were no cases with left ATs, but 24% had AT in the other 
group, despite having originally complete lines, without difference in AF recurrence rate.  
The authors concluded that in patients without structural heart disease linear ablation should 
be avoided as an initial ablation approach. Estner and co-authors demonstrated in their 
randomized study (47) that comparing PVI plus linear lesions or PVI plus additional CFAE 
ablation-so called „spot ablation” - the overall recurrence rate was similar, but the mode of 
recurrence was different: regular AT was the prevailing type of arrhythmia in the spot 
ablation group (11 vs. 29%, p=0.03). Furthermore, Rostock et al. (48) published a stepwise 
approach of persistent atrial fibrillation, including PVI and extended lesions in left and right 
atrium.  
Following this strategy, 40% of patients developed ATs during the follow-up. The prevalence 
of left atrial AT is 11 % in our population which is more common than in the study by 
Wasmer et al. (49), who published a 4% incidence in a very similar cohort recently. 
Organized ATs most commonly occurred several weeks to months after the AF ablation 
procedure, 8.8±7.7 months in our population, but sometimes during the initial attempt (either 
spontaneously or induced).  
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Mechanism - Focal AT 
The mechanism of atrial tachycardia varies with the ablation technique and to establish the 
exact mechanism of these tachycardias can be difficult and controversial which is especially 
true for the focal origin.  
A focal mechanism is usually suggested by the centrifugal activation pattern of the 
tachycardia on the electroanatomic maps.  
The mechanism most commonly is microreentry, non-reentrant types are usually caused by 
enhanced automaticity or triggered activity. The latter tachycardias are not so common; the 
prevalence probably does not exceed 10% of all ATs. Following segmental pulmonary vein 
isolation and partially after wide area antral ablation with confirming electrical isolation these 
tachycardias are typically focal in nature and related to recovered PV conduction, (41, 50, 51). 
In our series, it was 60 % of all ATs.  
Centrifugal activation pattern does not exclude reentrant mechanism by itself. This pattern 
can also be obtained from the exit site of a slowly conducting isthmus of a reentrant circuit, 
especially if the resolution of mapping is not high enough. Gerstenfeld et al. (41) performed a 
detailed pharmacologic and entrainment testing in a group of patients presenting with focal 
ATs following PVI.  
These maneuvers demonstrated that most of these ATs were due to localized small reentry 
circuits anchored to the slow conduction areas caused by the previous ablation. Only one of 
six ATs showed typical focal characteristics suggesting non reentrant mechanism (52). 
Similarly, Deisenhofer reported a series of LA ATs, using PVI plus additional lines during the 
first procedure. More than one third of these tachycardias were due to small reentrant circuits 
related to reconnected PVs (44). Shah et al. (53), demonstrated that 73% of ATs developing 
after AF ablation in their study were related to narrow, critical isthmuses at the vicinity of 
previously ablated PV ostial sites.  
Slow conduction in these areas was crucial for maintaining such a small reentrant circuit. 
These were 10-18 mm in size and produced rapid centrifugal activation in the rest of the LA. 
Interestingly, these critical isthmuses characterized by low amplitude-long duration 
intracardiac electrograms occupied almost half of the tachycardia cycle length and coincided 
with the isoelectric intervals in all 12 ECG leads, between flutter waves. (Fig. 3)  
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Figure 3. Twelve lead surface ECG of a narrow isthmus reentry, originating from the vicinity of right inferior 
pulmonary vein. Note the long isoelectric interval between discrete flutter waves. 
 
These observations were highly consistent with the results of Yokokawa et al. (54) in terms of 
the observation that extremely slow conduction and adjacent anatomical barriers play a 
critical role in stabilizing these microreentrant circuits.  
In the case of pulmonary vein tachycardia the pathologic impulse originates from the PV 
myocardial cells, and activates the LA through even a single recovered gap within the original 
lesion set. In the vast majority of cases, the rhythm within the PV is faster than in the LA, but 
sometimes 1:1 conduction can occur.  
After closing the gap(s) between LA and PV, the tachycardia should continue as a dissociated 
rhythm within the PV (Fig. 4). The mechanism of these tachycardias is not clearly elucidated. 
Some data from the literature supported that the mechanism is non-reentrant due to enhanced 
automaticity and triggered activity but others demonstrated evidences suggestive of reentry 
inside the pulmonary veins. 
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Figure 4. Rapid, regular pulmonary vein tachycardia persists within an isolated right superior pulmonary vein. 
The atria, outside the isolated vein are in sinus rhythm. (A). Radiofrequency ablation at the earliest spot within 
the vein, indicated by the ablation artifact on the 4-5 bipoles of Lasso catheter results in the termination of 
tachycardia. (B) Ls: lasso catheter, CS: coronary sinus catheter, Map d: mapping catheter. 
 
Macroreentrant AT 
Using anatomic ablation approaches with additional lines and/or CFAE ablation, the majority 
of ATs are macroreentrant, (73%-82%) which use regions of incomplete or recovered lesions 
and other anatomic obstacles.  
These tachycardias mostly revolve around the mitral valve (perimitral flutter, 28% of cases in 
our experience) or less commonly around the isolated pulmonary venous ostia (roof 
dependent flutter, 12% of cases), rarely around septal or posterior scars or LA appendage (44, 
51).  
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The arrhythmia circuits of these ATs are usually independent from the PVs, but sometimes 
the myocardial sleeves within the veins can contribute to generating such a mechanism. 
Satomi et al. (55) as well as Robinson et al. (56) presented clinical examples where the 
macroreentry circuits included the LA and PV myocardium as well, propagated via two 
conduction gaps located in the previous circular lesions which were relatively widely 
separated from each other (Fig. 5).  
It should be noted that most of these tachycardias presented with focal pattern on three 
dimensional electroanatomic maps (3D EAM), and could have been misdiagnosed as classical 
focal AT without detailed entrainment mapping guided by multipolar catheter within the PVs.  
Patients may also experience typical, cavo-tricuspid isthmus dependent right atrial flutter after 
AF ablation, which is not unusual in this population. The published prevalence of typical 
flutter is between 15%-30% (57, 58). 
 
Figure 5. Gap related tachycardia originating from the circular lesion around the right inferior pulmonary vein. 
(A, 200mm/sec), and the corresponding catheter positions, arrows point out the direction of activation through 
two gaps (at lasso pole number 4-5 and 7-8) in the ablation line (B). Entrainment pacing with 245 msec from the 
earliest lasso bipole (4-5) showed concealed fusion and PPI-TCL was 11 msec. (C). Termination of tachycardia 
during ablation at the entrance (pole 4-5) (D,100 mm/sec). The vein was isolated with the second ablation at the 
pole 7-8 (not shown). RIPV: right inferior pulmonary vein, CT: crista terminalis catheter, ICE: intracardiac 
echocardiography probe, Abl: ablation catheter, Lasso: lasso catheter, CS: coronary sinus catheter, PPI: post 
pacing interval, TCL: tachycardia cycle length. 
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Clinical management 
The initial treatment has to be conservative, considering that one third of ATs may resolve in 
time (45). The mechanism of spontaneous restoration is not clearly elucidated, but probably 
related to healing and changing substrate following the ablation. Understanding the 
mechanism (see earlier) of the AT before the redo ablation procedure could facilitate the 
mapping and ablation strategy of the tachyarrhythmia.  
Twelve lead surface ECGs can be helpful to distinguish between macroreentrant and focal 
arrhythmias: continuous activation is typical for macroreentrant mechanism, whilst isoelectric 
baseline between P waves suggests focal arrhythmias (53).  
As we already pointed out, in case of separated P waves with long isoelectric intervals in all 
12 leads one can anticipate a narrow isthmus reentry, caused by little electrical activity of 
slowly conducting isthmuses, coinciding with isoelectric lines.  
Some authors demonstrated that focal AT tends to be faster, than macroreentrant tachycardias 
(59), but others reported the opposite (57) or found no difference between them (49). P wave 
morphology can be useful to localize the source of the arrhythmia but this is very much 
dependent on preexisting scarring and the extent of previous ablation.  
In the electrophysiology laboratory, during an ongoing AT, our approach is to use multipolar 
catheters in the right atrium and coronary sinus (CS) and try to entrain the tachycardia first 
from the cavo-tricuspid isthmus (CTI) to exclude the possibility of typical right atrial flutter.  
After LA ablation of AF, sometimes typical atrial flutter shows atypical ECG findings (60) as 
for instance upright flutter waves in the inferior leads, which incorrectly suggests left atrial 
origin. However, this pacing maneuver may prevent unnecessary instrumentation of LA 
After exclusion of CTI dependent flutter or other right atrial sources, entrainment pacing is 
suggested from the distal and proximal electrodes of coronary sinus catheter. If the post-
pacing interval (PPI) minus tachycardia cycle length (TCL) is shorter than 30 msec. from 
those poles following termination of pacing which has resulted in atrial capture, the presence 
of perimitral flutter is very likely.  
Once a left atrial access is obtained, atrial tachycardias can be mapped by endocardial 
activation mapping and/or entrainment mapping. To exclude focal tachycardias related to PV 
reconnection, mapping of the four pulmonary vein ostia using circular catheter is 
recommended. If the mechanism is small or narrow isthmus reentry - which confines usually 
to typical reconnection sites of PVs, (septal aspect of right, and anterior sites of left PVs) (61) 
- entrainment pacing will show intracardiac evidence of concealed fusion and PPI-TCL from 
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a limited area, demonstrating mid-diastolic or long fractionated electrograms. Using 3D 
EAM, small reentry is considered when the majority of the cycle length can be accounted for 
during mapping and the diameter of the circuit is <3 cm. Re-isolation of PV(s) usually leads 
to termination of tachycardias.  
If the PV origin can be excluded, activation mapping has to be extended to typical sites of 
focal AT in LA, like posterior wall, LA appendage, and mitral annulus. The macroreentry is 
considered when the tachycardia is entrained with „in circuit” response from remote sites of 
LA, electrograms span all or most of the diastole, activation mapping accounts for at least 
85% of the tachycardia cycle length, as well as the diameter of the reentry circuit is >3 cm, 
and continuous propagation sequence with earliest and latest activation adjacent to each other 
on the EAM (57, 62).  
The most common form is the peri-mitral flutter traversing the mitral isthmus. In case of 
single loop peri-mitral circuit, there are several options to produce linear ablation lesions to 
terminate the tachycardia. The most common choice is the classical mitral isthmus line 
between the left inferior PV and the posterior mitral annulus (MA).  
Usually, it is a fairly long and concave isthmus, where one can have difficulties getting good 
contact without using intracardiac echocardiography. Histological data confirmed that 
coronary sinus muscle sleeves in this location are present in up to 75% of patients, and extend 
onto LA isthmus musculature.  
Not surprisingly, coronary sinus ablation is required in at least 70% of patients but 
bidirectional block cannot always be achieved (63). Another possibility is to create linear 
lesion from the right inferior PV to posterior MA, which is one the most difficult isthmuses 
because of the proximity of three different anatomical structures (right and LA and coronary 
sinus) and the slow pathway region.  
Next option is drawing lines from the right superior PV to anterior MA. This isthmus is 
usually longer than the posterior mitral isthmus, and this line passes the insertion of 
Bachmann bundle, which is relatively thick and may prevent the creation of a transmural 
lesion (Fig. 6). Several studies pointed out that failure to achieve bidirectional mitral isthmus 
block increased the risk of developing left atrial flutter. Anouseh et al. demonstrated (64) that 
in patients in whom mitral isthmus block was not achieved, there was a fourfold risk of 
occurrence of subsequent ATs.  
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Figure 6. A Perimitral reentry propagating around the mitral valve in counterclokwise direction on three 
dimensional CARTO activation map. Red dots represent the ablation line which was created between the 
anterior mitral annulus and the right superior pulmonary vein. Pannel B Roof dependent flutter propagating 
around the right sided pulmonary veins on three dimensional CARTO activation map with CT integration in 
right lateral view. RSPV: right superior pulmonary vein, RIPV: right inferior pulmonary vein, LSPV: left 
superior pulmonary vein, LIPV: left inferior pulmonary vein, LAA: left atrial appendage, MA mitral anulus.  
 
Macroreentry tachycardias around the isolated right of left side veins are less common, and in 
most patients completion of LA roof line leads to termination of tachycardias.  
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METHODS   
 
Study group 1 
 
Consecutive patients with manifest or concealed left-sided accessory pathway, without a 
history of AF (controls) and patients with paroxysmal AF scheduled for PVI, who had no 
symptomatic and/or documented AF episodes in the week prior to the procedure, were 
included. Exclusion criteria were persistent AF, CHADS2 (Congestive Heart Failure, 
Hypertension, Age, Diabetes, Stroke [Doubled]) score >2, previous LA ablation or open heart 
surgery, heart failure, reduced left ventricular function, and moderate to severe mitral 
regurgitation. 
 
Electrophysiologic procedures 
Informed consent was obtained and antiarrhythmic drugs have been discontinued for at least 
five half-lives at the time of the procedure. Using right ± left femoral vein access single 
(control patients) or double (AF patients) transseptal puncture was performed using 8.0 or 8.5 
French transseptal sheaths (Fast-Cath, St. Jude Medical, St. Paul, MN, USA), under 
intracardiac echocardiographic guidance.  
The side arm of the transseptal sheath was connected to a disposable pressure transducer 
(Combitrans, B. Braun, Melsungen, Germany), which was positioned and zeroed at a 
reference level 5 cm below the left sternal border, at the fourth intercostal space (65). Pressure 
was recorded at a sampling rate of 977/s by the CardioLab EP Recording System (GE 
Healthcare, Chalfont St Giles, UK). 
 
Pacing protocol 
The protocol was performed after the completion of the catheter ablation procedure, during 
the waiting period. At each site, pacing was performed with 2-ms stimulus duration, at twice 
diastolic threshold. Simultaneous atrioventricular (AV) pacing was carried out to produce an 
acute increase in LA pressure.  
LA ERP was determined both during simultaneous AV pacing and during atrial pacing at the 
same cycle length to control for the effect of the preceding cycle length on atrial ERP (Fig. 7). 
In AF patients, the atrial pacing catheter was positioned in the LA appendage; while in control 
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patients, LA ERP was determined by pacing from the distal bipole of the coronary sinus (CS) 
catheter to avoid the need for a second transseptal puncture.  
This has been previously shown to reflect LA ERP well (66, 67). Simultaneous AV pacing at 
a cycle length of 500 ms was carried out for at least 3 min to allow stabilization of pressure. 
Then, after every 30th drive stimulus progressively more premature (5-ms steps) atrial stimuli 
were introduced, without a pause in the drive train.  
LA ERP was defined as the longest coupling interval of the extrastimulus that failed to 
capture the atrium twice in succession. 
 
Figure 7. Determination of LA effective refractory period (ERP) during atrial pacing (a) and during 
simultaneous AV pacing (b). LAA LA appendage, LAP left atrial pressure, RV right ventricle.Coupling intervals 
(CI) of extrastimuli are shown in milliseconds. ERP is defined as the longest CI without atrial capture 
 
Echocardiographic measurements 
All patients underwent comprehensive two-dimensional transthoracic echocardiography 
examination using a commercially available ultrasound machine (Vivid I, GE Medical 
Systems, Horten, Norway) equipped with  a 2.5–3.5-MHz phased array transducer and 
software application for two-dimensional speckle tracking-based strain imaging.  
LA volumes were calculated using the biplane method of disks (modified Simpson’s rule), in 
the apical 4- and 2- chamber view at end-systole (maximum LA size), and a mean value of 
volume was obtained (68).  
LA volumes were indexed (LAVI) to body surface area (BSA). Mitral annular velocity was 
evaluated by tissue Doppler in the pulsed-wave mode (69). 
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Assessment of left atrial reservoir function 
Particular attention was paid to obtain an adequate twodimensional- grayscale image, 
allowing obvious delineation of LA wall and extracardiac structures.  
The frame rate was set between 60 and 80 frames per second. Three consecutive heart cycles 
were recorded at baseline and immediately after simultaneous AV pacing (Fig. 8). Recordings 
were processed using acoustic-tracking software (EchoPac PC version 110.1.8, GE 
Healthcare, Horten, Norway), allowing off-line semiautomated analysis of speckle tracking-
based strain (70). 
In the end-diastolic/systolic frame, the atrial endocardial border was marked by a point-and-
click method. After automatic creation of a region of interest, the LA wall was divided into 
six regions, and segmental tracking quality was analyzed (Fig. 8).  
The reference point was set at the onset of the QRS, and the average positive peak atrial 
longitudinal strain (PALS), which corresponds to LA reservoir function, was measured (Fig. 
8). Values from the three consecutive cycles were averaged (71).  
The LA stiffness index (SI) was calculated as mean LA pressure (LAP)/PALS(72) 
 
 
 
Figure 8. Measurement of peak atrial longitudinal strain (PALS) immediately after simultaneousAV pacing. The 
dashed curve represents the average PALS. 
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Study Group 2 
 
Thirty-one consecutive patients undergoing their first PVI for drug-refractory, symptomatic 
PAF (53±9 years old, 17 men) were prospectively studied.  
All patients gave their written informed consent to participate in the study. Exclusion criteria 
were previous left atrial (LA) catheter ablation or open-heart surgery, persistent AF, severe 
valvular heart disease, or LA thrombus.  
Patients without inducible sustained PAF during the study (two patients) and those with PAF 
triggers originating from extra-PV sites (two patients) were also excluded. 
 
Electrophysiologic procedure 
Patients were on oral anticoagulation for at least 3 weeks before the ablation, and 
transesophageal echocardiography was performed to exclude any atrial thrombi before the 
procedure.  
All antiarrhythmic drugs were discontinued for at least five half-lives except amiodarone 
which was discontinued 1 month prior to the procedure. The study was performed as 
described previously (73). Briefly, under conscious sedation (midazolam ±fentanyl), 
following femoral venous access, two decapolar steerable catheters (interelectrode spacing 2–
5–2 mm, Dynamic Deca; Bard Electrophysiology, Lowell, MA, USA) were positioned in the 
coronary sinus and the posterolateral right atrium.  
The LA and the PVs were mapped through double transseptal puncture. Intracardiac 
echocardiography (ICE) (AcuNav; Acuson Corp., Mountain View, CA, USA) was used for 
performing the transseptal puncture and to guide catheter positioning. A decapolar circular 
mapping catheter (CMC) (Inquiry Optima, St Jude Medical, Irvine, CA, USA) was positioned 
at the left PV antrum overlying both left PVs, and a 3.5 mm irrigated-tip mapping catheter 
(Navistar Thermocool, Biosense Webster, Diamond Bar, LA, USA) was positioned on the 
right PV carina. (Fig 9) 
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Figure 9. Left anterior oblique (LAO) and right anterior oblique (RAO) view showing the two decapolar 
catheters placed in the coronary sinus (CS) and right atrium (RA), circular mapping catheter (CMC) in the left 
pulmonary veins (PVs) and mapping catheter (ABL) in right PVs. 
 
Assessment of the triggering PVs and signal analysis 
The CMC was positioned at the left PVantrum overlying both left PVs, and the mapping 
catheter was positioned on the right PV carina. If the patient presented in sinus rhythm, PAF 
was induced by isoproterenol infusion, starting at 3 μg/min with incremental doses of 5μg/min 
until PAF was induced, the maximum dose of 20 μg/min was reached, or the patient 
developed side effects.  
If the patient was in AF, first, we performed transthoracic electrical cardioversion before PAF 
induction. Ectopic activity triggering a PAF episode was identified, and the origin was 
determined based on the endocardial activation sequence and by comparison to paced 
activation sequences from PVs as well as observing LA-PV electrogram reversal as 
previously described (73). Triggering activity was considered to originate from the right PVs 
when earliest activation and LA-PV electrogram reversal were recorded using the mapping 
catheter at the right PV carina.  
When earliest activation was recorded using the CMC, left upper or lower PV origin was 
determined based on the radiographic position of poles recording the earliest activity. After 
induction, isoproterenol administration was stopped and further recordings were made after a 
5-min washout period.  
During sustained PAF, the CMC was used to record sequentially from each PV ostium. Signals 
were recorded for at least 30 s at a sampling rate of 997 Hz using a digital EP recording system 
(GE CardioLab; General Electric, Milwaukee, WI, USA) and were stored for offline analysis.  
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Intracardiac recordings were analyzed, utilizing a custom-designed computer application 
prepared with the LabView software package (National Instruments, Austin, TX, USA). 
Signals were filtered between 30 and 500 Hz, rectified, and low-pass filtered at 20 Hz. A fast 
Fourier transformation (FFT) was performed on two consecutive 5-s episodes from each 
bipole of the CMC. The frequency spectrum in the 3–15 Hz range was obtained, and the peak 
with the highest power was determined as the dominant frequency (DF).  
Noisy and highly disorganized signals (organization index<0.25) were excluded from the 
analysis (73). The DFs of consecutive 5-s episodes were averaged, and the maximum DF 
value of all bipoles was taken as the DF of that PV and used for analysis (Fig. 10). 
 
 
Figure 10. Surface ECG leads I, II, V1, and V6, together with intracardiac recordings from the right atrium (RA) 
and circular mapping catheter (CMC) placed in the left pulmonary vein antrum (a), left superior pulmonary vein 
(LSPV, b), and left inferior pulmonary vein (LIPV, c) and from the proximal to distal coronary sinus (CS). Atrial 
fibrillation is initiated by rapid discharge from the LSPV (a). Following isolation of the vein, sustained 
dissociated rhythm with intermittent burst activity was recorded (b). Sporadic dissociated activity was recorded 
in the LIPV after isolation (c). In the right pulmonary veins, there was no dissociated activity after isolation. 
Dominant frequency (DF) distribution during sustained atrial fibrillation in the same patient (d) 
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Assessment of DiFi 
After electrical disconnection of all PVs, each PV was assessed periodically during a 30-min 
waiting period for the presence of DiFi.  
The CMC was positioned in one PV for 30 s and then moved to the next, repeating 
periodically during the waiting period.  
Rhythm in the PV was classified as follows: 1=absent (if there was no electrical activity at 
all), 2=sporadic DiFi (scarce and fortuitous occurrence of dissociated potentials without a 
regular rhythm), and 3=sustained DiFi (regular ectopic rhythm or isolated PV tachycardia) 
(Fig. 10 b,c). 
 
Measurement of the PV ostial area 
The LA and PVs were segmented from high-resolution computed tomography (CT) volumes 
using the CARTO system (Biosense Webster, Baldwin Park, CA, USA), and cut planes were 
positioned to separate the PVs from the body of the LA.  
Using area measurement tools of the CARTO system, we measured the cross-sectional area 
and the perimeter of the ostium of the PVs. We chose to determine the area of the ostium of 
PVs because it can be measured with greater precision than the mean diameter (74-75). 
 
Follow-up and redo procedures 
All patients had a follow-up visit at 3, 6, and 12 months. Seven-day Holter monitoring was 
performed when a patient had no symptoms at least 6 months after ablation to reveal 
asymptomatic recurrence or when patients reported symptoms suggestive of recurrence 
without documented arrhythmia.  
In case of recurrence, patients were offered a second procedure, during which reisolation of 
reconnected PVs was performed. No additional ablation of non-PV triggers or substrate 
outside the PV antra was undertaken.  
Since permanent isolation of PVs often requires a second attempt, we evaluated the success of 
PVI after the last procedure and defined it as freedom from any sustained (>30 s) atrial 
arrhythmia (symptomatic or asymptomatic), off antiarrhythmic drugs. 
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Study Group 3 
 
Forty patients (16 women, mean age 60±12 years) with paroxysmal AF, referred for catheter 
ablation comprised Study Group 3. The study was approved by the Institutional Review 
Board of the University of Szeged (no. 41-83).  
All patients gave their written informed consent to participate in the study. Exclusion criteria 
were previous left atrial (LA) catheter ablation or open heart surgery, persistent AF, severe 
valvular heart disease or LA thrombus. Patients were prospectively included and received 
Ado and Iso for induction in a randomized order (76). 
 
Drug Challenge 
If the patient presented in AF, DCCV was performed to restore sinus rhythm and evaluate for 
spontaneous re-initiation and identifying post cardioversion AF triggers. If the presenting 
rhythm was sinus or AF was not spontaneously reinitiated after the cardioversion, we 
proceeded with the drug challenge. 
Isoproterenol (Iso) was infused via a short femoral venous sheath in incremental doses 
starting at 3μg/min and increasing after 3-5 minutes to 5 μg/min, 10 μg/min, 15 μg/min, and a 
maximum dose of 20 μg/min, until induction of AF or intolerable side effects occurred. 
Adenosine (Ado) was administered into the right atrium (RA) via one long transseptal sheath 
that was pulled back in the RA. A quick bolus of 18 mg was given flushed with 5-10 ml of 
saline. A second dose of 36 mg was administered if AF was not induced after the first dose. 
Ectopic activity triggering an AF episode was identified and the origin determined based on 
the endocardial activation sequence, as described above for Study Group 2. Triggers of AF 
were considered to arise from the left PVs if the earliest activation and LA-PV electrogram 
reversal was recorded on the CMC and from the right PVs if the earliest atrial activation was 
recorded on the mapping catheter positioned at the right PV carina. If earliest atrial activation 
during bursts of ectopic activity initiating AF was recorded at any of the CS or RA bipoles, 
then these structures were identified as the origin of triggers. (Fig 11) 
The order in which the two drugs were administered (Iso first or Ado first) was randomized in 
a 1:1 fashion. When sustained AF was induced and did not terminate after a few minutes, 
DCCV was performed and the second drug was administered after a 5-minute waiting period. 
In cases when immediate recurrence of AF (IRAF) occurred after DCCV, drug challenge was 
terminated and we proceeded with ablation. We determined the effectiveness of the two drugs 
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in inducing AF and compared them with each other and spontaneous AF episodes in terms of 
the location of AF triggers. 
 
 
 
Figure 11. Surface electrocardiogram lead I, II, V6 along with intracardiac recordings from right atrium (RA), 
coronary sinus (CS) and circular mapping catheter (CMC) placed in the pulmonary vein (PV) antrum, during 
initiation of atrial fibrillation.  Panel (A) during adenosine infusion AF was induced from RA.  Spontaneously 
(Panel B) and during isoproterenol infusion (Panel C) AF was induced from the PVs. Paper speed=75mm/s. 
During redo procedure only the previous triggering pulmonary vein was reconnected (Panel D). Paper 
speed=100mm/s.  
 
Catheter ablation  
In patients undergoing a PV isolation procedure a 3-dimensional electroanatomic shell of the 
LA was created. Circumferential, irrigated radiofrequency ablation lesions were delivered 
around ipsilateral PVs using the mapping catheter, with the endpoint of electrical isolation 
manifested in exit and entrance block between LA and PVs.  
The decision to selectively isolate only the left or right PVs - whichever were shown to be 
arrhythmogenic during drug challenge - or empirically isolate all 4 PVs was at the discretion 
of the operator.  
However, in case of a redo procedure all 4 PVs were isolated, irrespective of the initial 
approach.  
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Statistical analysis 
Continuous variables are reported as mean±SD and compared using one-way analysis of 
variance (ANOVA) and Student’s t test.  
Categorical variables are presented as percentage and compared using the chi-square test. 
Kaplan-Meier survival analysis was used to estimate the mean time to recurrent AF after the 
procedure. Survival curves were compared using the log-rank test.  
All statistical analyses were performed using the SPSS software version 16 (IBM Inc., NY, 
USA). A p value <0.05 was considered statistically significant. 
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RESULTS 
 
Acute pressure elevation in controls and patients with AF 
In Study Group 1 eleven controls and 16 patients with paroxysmal AF were included. 
Controls were younger and had smaller LA volume index (LAVI), without further differences 
in clinical characteristics (Table 1). Patients with AF had higher mean (mLAP) and peak 
(pLAP) invasive LA pressures at baseline (8.3±4.7 vs. 5.1± 3.1 mmHg, p=0.048 and 20.8±8.8 
vs. 14.6±5.7 mmHg, p= 0.015, respectively), compared to controls. Baseline LA PALS was 
significantly lower (15.1±5.1 vs. 21.6±6.2 %, p=0.006), while baseline SI was higher 
(0.69±0.75 vs. 0.28±0.22, p=0.015), pointing to diminished LA reservoir function in patients 
with AF. At the same time, LA ERP was longer at baseline in AF patients, compared to 
controls (242.3±33.4 vs. 211.7±15.6 ms, p=0.017). 
 
 
Table 1. Baseline clinical and echocardiographic parameters 
 
Left atrial pressure elevation 
During simultaneous AV pacing, mLAP rose by the same extent in controls and AF patients 
(mean change 12.6±7.4 vs. 12.6±7.5 mmHg, p=0.980). At the same time, LA PALS decreased 
(from 15.1±5.1 to 11.6±3.3 %, p=0.008) and SI increased (from 0.69±0.75 to 1.29±1.17, p<0.001) 
in patients with AF, while they remained unchanged in controls (from 21.6±6.2 to 22.9±7.1 %, 
p=0.405 and from 0.28±0.22 to 0.45±0.43, p=0.10, respectively). With pressure elevation, LA 
ERP decreased in AF patients (from 242.3±33.4 to 215.9 ±26.3 ms, p=0.003) but was not 
changed significantly in controls (from 211.9±16.7 to 206.3±19.6 ms, p=0.276) (Fig. 12). 
 
 Controls AF patients p-value 
Age (year) 42.2±21.1 60.3±8.8 0.019 
Female (%) 22 31 0.629 
BSA (m2) 1.91±0.22 1.98±0.22 0.381 
Hypertension (%) 27 56 0.137 
Diabetes (%) 0 0  
CHADS2 score 0.22±0.44 0.75±0.68 0.084 
LVEF (%) 64.7±6.8 59.8±3.7 0.189 
Ea (cm/s) 12.0±2.6 10.4±3.3 0.331 
LAVI (ml/m2) 32.4±11.4 59.4±12.1 <0.001 
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Figure 12. Changes in mean LA pressure (LAP), LA strain (PALS), stiffness index (SI), and refractory period 
(ERP) in response to simultaneous AV pacing in controls and AF patients. Stars mark significant (p<0.05) 
changes. 
 
Follow-up 
Four of 16 AF patients (25 %) experienced arrhythmia recurrence after pulmonary vein 
isolation, during 16±7 months of follow-up. Patients with recurrence had lower baseline LA 
reservoir function (PALS = 10.7±3.2 vs. 16.7±4.0 %, p=0.036), compared to those without. 
 
Association between dissociated firing in isolated pulmonary veins and atrial fibrillation 
Baseline characteristics of the patients from Study Group 2 are presented in Table 2. PAF 
triggers were found to originate from the left superior PV (LSVP) in 20 (65%) patients, from 
the left inferior PV (LIPV) in 5 (16%) patients, and from the right PVs in 6 (19%) patients. 
Electrical isolation of PVs by circumferential ablation was achieved in all patients. Fourteen 
(45%) patients had DiFi after PVI in at least one and 7 of them in more than one PV. It was 
recorded most commonly from the left upper (84%) and lower (67%) and less commonly 
from the right upper (31%) PVs. Out of the 23 PVs with DiFi, 13 (57%) showed sporadic 
ectopic beats while 10 (44%) had sustained ectopic rhythm or isolated tachycardia. No further 
ablation was performed to abolish this dissociated rhythm. There was no difference in size 
between PVs with or without DiFi (5.9±1.2 vs. 5.6±1.0 cm ostial perimeter, p=0.40, and 
2.7±1.1 vs. 2.4±0.9 cm2 ostial area, p=0.55). 
 31 
Variable No DiFi DiFi p value 
Age (years) 54 ± 9.6 52 ± 8.5 0.27 
Men (%) 41 71 0.19 
PAF duration (months) 63.5 ± 53.3 58.9 ± 67.4 0.42 
Hypertension (%) 65 69 0.79 
Coronary disease (%) 6 8 0.84 
Diabetes (%) 12 8 0.71 
Left atrial diameter (mm) 45.08 ± 3.4 45.45 ± 6.9 0.43 
LVEF (%) 61 ± 6.28 64.81 ± 6.54 0.08 
 
Table 2. Clinical characteristics of patients with and without dissociated firing (DiFi) after PVI for paroxysmal 
atrial fibrillation (PAF). 
 
Association between PV triggers and DiFi 
Triggering PVs more commonly showed any DiFi, compared to nontriggering PVs (68 vs. 27 
%, p=0.003) and more commonly had sustained DiFi (53 vs. 0 %, p<0.001) (Fig. 13). Thus, 
the triggering vein was more likely to have dissociated ectopy after isolation. 
 
Figure 13. Distribution of the different types of dissociated firing (DiFi) following isolation in PVs with atrial 
fibrillation triggers versus nontriggering PVs. 
 
Association between DF and DiFi 
During sustained PAF, PVs with any DiFi showed faster maximal DF compared to PVs 
without DiFi (7.1±1.3 vs. 5.9± 1.1 Hz, p=0.001). Higher maximal DF was recorded in PVs 
with sustained versus sporadic DiFi versus PVs without DiFi (7.5±0.9 vs. 6.8±1.6 vs. 5.9±1.1 
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Hz, respectively, p=0.002) (Fig. 14). The maximal DF was higher in triggering PVs, 
compared to nontriggering ones (8.02±1.64 vs. 6.53±1.36, p<0.001). 
 
Figure 14. Dominant frequency (DF) during atrial fibrillation in PVs showing different types of dissociated 
firing (DiFi) after isolation 
 
Clinical outcome 
During the ablation procedure and a mean of 31±18 months of follow-up, no major 
complication occurred in any patient. Ten patients (32%) underwent a redo PVI procedure, 
and all of them had reconnected PVs which were reisolated. There was no difference in the 
redo rate between groups (29 vs. 35 %, p=0.690, for patients with and without DiFi, 
respectively).  
Two patients (14%) with DiFi and seven patients (41%) without DiFi had a recurrence after 
the last procedure. One of the two patients with DiFi had asymptomatic recurrence and 
refused a second procedure. The difference in recurrence rate did not reach statistical 
significance (p=0.101).  
However, patients with DiFi after PVI had a longer mean time to recurrent PAF after the last 
procedure compared to those without DiFi at the index procedure (52 vs. 32 months, p= 
0.048) (Fig. 15). 
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Figure 15. Kaplan-Meier curve of the freedom from arrhythmia recurrence. Patients with dissociated firing 
(DiFi) after PVI (continuous line) had a longer mean time to recurrence compared to those without DiFi (broken 
line) 
 
Isoproterenol versus adenosine for the identification of atrial fibrillation triggers 
Four (10%) patients from Study Group 3 could not receive any drug challenge because their 
spontaneous AF ongoing at the commencement of the procedure restarted immediately after 
DCCV. Eighteen of the remaining 36 patients were randomized to receive Iso first and 18 
Ado first. In case of 10 (28%) patients the second drug was not given, because the AF 
induced by the first drug spontaneously restarted after DCCV. Therefore 36 (90%) patients 
received their first and 26/36 (72%) patients the second drug. Altogether 32 patients received 
Iso and 30 patients Ado (30 received 18 mg, 21 received 18 and 36 mg). AF was induced with 
Iso in 15/32 (47%) and with Ado in 12/30 (40%) patients (p=0.9). Iso-triggered AF started 
from the left PVs in 11 (73%), from the right PVs in 3 (20%), from the CS in 1 (7%) cases 
(Figure 16A). Ado-induced AF episodes originated from the left PVs in 6 (50%), from the RA 
in 4 (33%), from the CS in 2 (17%) cases (Figure 16B). Altogether Iso-induced AF was more 
likely initiated from the PVs (93%), compared to Ado (50%) (p=0.02). 
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Figure 16. Trigger sites of isoproterenol induced AF (Panel A) and adenosine induced AF (Panel B). 
 
Of the 26 (72%) patients (Figure 17, Table 3.) who received both drugs, AF could not be 
induced by drug challenge in 13 (50%). Iso triggered AF in 9/26 (35%) patients; all triggers 
were localized to the PVs (7 left, 2 right PVs). Ado was effective at inducing AF in 8/26 
(31%), 2 from left PVs and 6 from non-PV sites (4 RA, 2 CS, p<0.01 versus Iso). Both drugs 
induced AF in 4/26 (15%) of these cases. In 2 of those 4 patients triggers originated from the 
left PVs with both Iso and Ado, while in the remaining two cases there was discordance 
between the two drugs, Ado manifesting non-PV triggers. 
 
Figure 17. Study flowchart. IRAF: immediate recurrence of atrial fibrillation (AF) after cardioversion, Ado: 
adenosine, Iso: isoproterenol, LPV: left pulmonary veins (PV), RPV: right PV, RA: right atrium, CS: coronary sinus 
 
Fourteen (35%) patients had spontaneous AF during the procedure, 13 (93%) originated from 
the PVs (9 left, 4 right PVs), and only one from the CS. Ten of these cases received one or 
both drugs. Iso reproduced left or right PV triggers in 6/7 cases and was ineffective in one. 
Ado reproduced left PV triggers in 4/7 cases, but was ineffective in 3. This results in a 
sensitivity to reproduce spontaneous triggers of 86% for Iso and 57% for Ado. 
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Patient # First drug 
Isoproterenol Adenosine 
Spontaneous 
triggers Max. dose 
(µg/min) 
Induced 
triggers 
Max. dose 
(mg) 
Induced 
triggers 
1 Ado 10 LPV 18 RA - 
2 Ado 20 LPV 18 LPV LPV 
3 Iso 20 LPV 18 LPV - 
4 Iso 20 - 18 RA - 
5 Ado 20 - 18 RA - 
6 Ado 20 LPV 36 - - 
7 Ado 20 LPV 36 - - 
8 Iso 5 LPV 36 CS - 
9 Ado 20 LPV 36 - - 
10 Iso 15 RPV 36 - RPV 
11 Iso 3 LPV 36 - LPV 
12 Iso 20 - 36 - - 
13 Ado 20 - 36 - - 
14 Iso 20 - 36 - - 
15 Ado 20 - 36 - LPV 
16 Ado 20 - 36 - - 
17 Ado 20 - 36 - - 
18 Ado 20 - 36 - - 
19 Iso 20 - 36 - - 
20 Iso 20 - 36 - - 
21 Iso 20 - 36 - - 
22 Ado 20 - 36 - - 
23 Iso 20 - 36 CS - 
24 Ado 20 - 36 - - 
25 Iso 20 - 36 RA - 
26 Ado 20 - 36 - - 
Table 3. Characteristics of patients who received both drugs. Abbreviations are as on Figure 17. 
 
After drug testing 38 of 40 (95%) patients underwent PVI. Two patients – for whom initially a 
selective PVI was planned - did not have an ablation (one was noninducible and one had RA trigger 
on Ado). Thirty of the remaining 38 (79%) received empirical isolation of all 4 PVs, while 8 (21%) 
patients a selective PVI of arrhythmogenic PVs. Ten of 38 (26%) underwent a second PVI 
procedure with the aim of 4-PV isolation, because of recurrence of AF. After the last procedure, 32 
of 38 (84%) ablated patients were free of recurrence during 16±9 months of follow-up. 
Of the 14 patients who had PV triggers disclosed by Iso infusion, one was lost to follow-up, 
and the rest had no AF recurrence after the last PVI. In case of the only patient with a non-PV 
trigger on Iso PVI was ineffective, even after a redo procedure. Among the 6 patients with PV 
triggers on Ado, PVI and redo PVI failed in one. Of the 6 patients with non-PV triggers on 
Ado, one was not ablated and one failed PVI and a redo. The remaining 4 are without 
recurrence after the last procedure. Therefore, while Iso was 100% accurate in predicting a 
favorable response to PVI, the accuracy of Ado challenge was only 55%. There was no 
correlation between non-PV triggers induced by Ado and arrhythmia recurrence after the last 
procedure (p=0.90). 
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DISCUSSION  
 
During the last decade, numerous data became available regarding the long-term efficacy of 
the interventional treatment of atrial fibrillation. These data can be especially important for 
estimating prognosis, evaluation of currently available ablation techniques, and last but not 
least for the reimbursement policy of procedures.  
To summarize the results of our literature review, we can conclude that long-term freedom 
from AF is achievable and maintainable over 2-3 years or even more with mild increases in 
arrhythmia recurrence over time. This statement is especially true for the paroxysmal AF 
population, following initial PVI procedures.  
Single procedure success rate is definitely lower in the long-term, so for achieving a durable 
result, multiple procedures have to be taken into account. The success of an ablation 
procedure is less encouraging in the persistent population, moreover there is no real consensus 
regarding the best ablation strategy beyond PVI, to improve the long-term efficacy rate.  
It is likely that the main mechanism behind very late recurrences of AF is the PV 
reconduction and recurrent PVs triggers, but progressive remodeling of left atrial substrate as 
well as non- PV triggers can play an important role over time, especially in the persistent AF 
population.  
It should be noted that strict AF free success rates in both groups probably underestimate the 
real long-term clinical benefit of the procedures if we focus on symptomatic improvement or 
fewer hospitalizations.  
Furthermore, it cannot be overemphasized that studies demonstrating very different results 
regarding the outcome of procedures are showing significant heterogeneity in terms of the 
definition of success, methodology of follow-up, and the applied ablation technologies. 
One of the most important proarrhythmic complications after catheter ablation of AF is 
regular atrial tachycardia (AT) or flutter. ATs occur relatively frequently after AF ablation 
procedures.  
The incidence of these tachycardias varies in the context of previous lesion set and probably 
of the extent of abnormal atrial electrophysiologic substrate. The mechanism in vast majority 
of cases is reentry related to gaps in prior ablation lines.  
Conservative therapy is usually not effective; radiofrequency ablation procedure is mostly 
successful but can be challenging and requires a complex approach. 
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Left atrial mechanoelectric feedback 
Understanding the pathophysiologic mechanisms that lead to AF initiation and persistence is 
very important in improving the outcome of the procedure. Atrial pressure elevation 
predisposes to atrial fibrillation by several mechanisms.  
Acute atrial pressure increase leads to electrophysiologic changes, while chronic atrial stretch 
also induces structural remodeling. We have seen a dramatic fall in ERP and reservoir 
function in response to pressure rise in patients with AF, which did not happen in the normal 
LA. We conclude that the normal adaptation to acute elevations in LA pressure is lost in 
patients with AF, even during sustained sinus rhythm. 
Even when in sinus rhythm, patients with paroxysmal AF show diminished LA reservoir 
function estimated by LA strain (77, 78). We have shown that LA strain is also dependent on 
LA pressure in patients with AF, and an acute rise in pressure leads to a decline in LA 
reservoir function and increased stiffness, a response not observed in the normal LA. In 
patients with paroxysmal AF, but without a recent episode, LA ERP measured at the LA 
appendage has been shown by some (79, 80), but not by other reports (81) to be longer than in 
controls, while it was consistently shorter in patients with persistent AF. The reason for this 
inconsistency might be the dependence of atrial refractoriness on pressure, a phenomenon 
known as mechanoelectric feedback (82).  
Mechanoelectric feedback is well described in the ventricles, has been shown at the atrial 
level and in the human right atrium, but has not been studied in the human LA, the major 
source of AF (83-87). Acute atrial stretch increases vulnerability to AF in both animal models 
and humans (88, 89); the mechanism most commonly considered behind this is a shortening 
of refractoriness and slowing of impulse conduction (90-92), both promoting the development 
of reentry.  
We have shown that pressure-related shortening of refractoriness-mechanoelectric feedback-is 
magnified in the LA of patients with AF, which likely facilitates the persistence of the 
arrhythmia. Paroxysmal AF itself leads to atrial pressure elevation (93).  
According to our study, increased atrial pressure can result in increased stiffness and wall 
tension with shortened atrial refractoriness favoring AF maintenance. This way, a vicious 
circle is established, which may culminate in persistent AF. These results therefore suggest 
early intervention to prevent the progression of AF. 
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Dissociated firing (DiFi) from PVs 
Trying to obtain a better outcome of PVI we searched if dissociated firing (DiFi) in isolated 
PVs implies arrhythmogenicity of the particular PV.  
The main finding of our study is that PVs with DiFi after isolation show higher activation rate 
during fibrillation and, therefore, are more likely to have a role in the perpetuation of atrial 
fibrillation as compared to PVs without DiFi.  
Furthermore, PVs showing DiFi more frequently initiate atrial fibrillation. Therefore, DiFi 
after PVI can be considered a hallmark of PV arrhythmogenicity pointing to the role of the 
particular PV both in the initiation and maintenance of PAF. When PAF is initiated and 
maintained by PV arrhythmogenicity rather than other mechanisms, PVI should have a better 
outcome. 
 
Mechanism of DiFi 
Spontaneous electrical activity of PVs after isolation presents as DiFi. It is either an escape 
rhythm overridden by the faster sinus node (SN) before isolation and unmasked by PVI or 
rapid ectopic triggering no longer capable of initiating PAF after isolation.  
Specialized cells resembling those of the SN have been described in the PVs and are thought 
to be responsible for spontaneous automaticity (94-95) manifested as DiFi after PVI, which 
shows a pharmacological response similar to sinus rhythm (96).  
However, PV electrical activity triggering PAF may have a mechanism that is different from 
the slow escape rhythm type of DiFi. Its mechanism is more compatible with triggered 
activity (97), being provoked by rapid pacing and the autonomic effects of adenosine (98), 
rather than being suppressed. This type of activity most commonly is eliminated by 
circumferential ablation around the PVs, possibly due to the effects of ablation on the 
autonomic nervous system (99). Therefore, the association between DiFi and PV 
arrhythmogenicity deserves further investigation. 
 
Incidence of DiFi after PVI 
The incidence of DiFi after PVI shows a broad variation from 2.8 to 92% (96, 100). This 
variation may be explained by differences in the definition of dissociated activity, study 
population, or ablation approach. Kabra et al. (100) reported an incidence of 92% of DiFi 
after PVI for PAF, and similar to our study, the DiFi was classified as isolated ectopic beats, 
ectopic regular rhythm, or PV fibrillation.  
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In contrast, Buiatti et al. (101) in a recent study reported that 27% of their patients had at least 
one vein (12% of PVs) with DiFi, but the investigators took a unique approach to define the 
dissociated activity (slow intermittent potentials without a regular rhythm) and excluded most 
of what we have defined as DiFi.  
In our study, the incidence of DiFi was 45% of PAF patients presenting for PVI. Consistent 
with a previous study (102), we observed a higher proportion of DiFi originating from 
superior PVs compared to inferior veins.  
Also, PAF was triggered most commonly from upper PVs, similar to previous reports (103). 
This may be related to thicker muscle sleeves (104) Guerra et al. (105) linked areas of PV 
wall thickening to high-frequency potentials and the origin of ectopic beats.  
We could not find any significant correlation between the size of PVs and the presence of 
dissociated activity after isolation. The ablation technique also has an impact on the 
occurrence of DiFi after PVI.  
Segmental, ostial isolation resulted in a DiFi rate of 5-33% (106), while wide-area encircling 
ablation resulted in up to 85-92% (100, 106, 107). This suggests that ablation closer to or 
inside the PV ostium (e.g., at the carina) can destroy some of the foci responsible for DiFi. 
 
Prognostic implications of DiFi 
Similar to the above mentioned reports defining the incidence and characteristics of DiFi, 
studies on the impact of dissociated activity on the outcome of PVI are also conflicting. Some 
have shown improved outcome of PVI in patients with DiFi (108, 109)and better success rate 
when the foci of DiFi were ablated inside the PVI lesions, rather than left untouched.  
However, others have reported either no difference (101, 102, 110) or even increased 
recurrence rate in the case of DiFi that is not ablated (111).  
The explanation for an improved success rate in the aforementioned studies is either that DiFi 
is a marker of more proximal and better quality ablation lesions, providing evidence of exit 
block from the PVs (8) or that DiFi is a marker of PV arrhythmogenicity (7). 
 
Relation between DiFi and PV arrhythmogenicity 
Although, in two previous studies, the association between triggering PVs and DiFi was 
assessed (101,108), a systematic approach to PAF induction was not employed and the 
proportion of patients with the triggering structure identified was low (10 and 44.5%, 
respectively). Furthermore, the definition of triggering and DiFi was variable. One of these 
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studies (101) suggested an association between PVs with PAF triggers and DiFi, while in the 
other, it was not significant (108).  
We included only patients with the triggering PV identified (defined as the vein from which 
ectopic activity initiated PAF) and observed a significantly higher incidence of DiFi after 
isolation of a triggering PV, compared to nontriggering ones. This suggests that PVs with 
DiFi after PVI are more likely to have a role as initiators of PAF. We previously described 
(73) that triggering PVs showed the fastest activity during sustained PAF, pointing to their 
role not only in the initiation but also in the perpetuation of the arrhythmia.  
In this study, we observed that PVs with DiFi showed faster maximal DF during PAF 
compared to PVs without DiFi, suggesting an association between DiFi and the maintenance 
of PAF. In addition, the correlation between DiFi and arrhythmogenicity of a PV both as 
initiator and perpetuator of PAF became more pronounced with more expressed (sustained vs. 
sporadic) DiFi. In line with the above and similar to studies showing DiFi to be a positive 
predictor of success (7, 8), we found that patients with DiFi after PVI had a longer mean time 
to recurrent PAF compared to those without DiFi. 
These results confirm that observing DiFi from isolated PVs is related to the 
arrhythmogenicity of the PV. The presence of DiFi is associated with a better outcome of PVI 
not because the quality of PVI is higher but because it implies that PAF is more likely to have 
a PV-based mechanism for the particular patient. On the contrary, patients without DiFi after 
PVI are more likely to have non-PV mechanisms and more advanced atrial substrate involved 
in the arrhythmia. This is further supported by previous studies finding more structural heart 
disease (6, 110), hypertension (7), and non-paroxysmal atrial fibrillation (110) among cases 
without DiFi and a trend for a lower left ventricular ejection fraction in our study. 
 
Induction of AF triggers in the electrophysiology lab 
AF catheter ablation can be more successful by identifying and eliminating sites that can 
trigger paroxysmal and persistent AF. Identification and ablation of non PV triggers after PVI 
has been associated with improved arrhythmia free survival. Besides isoprenaline (Iso), 
adenosine (Ado) can be used for the induction of atrial fibrillation (AF) during 
electrophysiology studies, however data are lacking on the sensitivity and specificity of Ado-
challenge. The main finding of our study is that, while Iso mostly induces PV triggers, Ado is 
more likely to induce non-PV triggers of AF, dominantly from the RA. Half of Ado-inducible 
patients had AF from non-PV sites, compared with only 7% with Iso. Moreover, in two cases 
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the two drugs showed divergent effects in the same patient: Ado inducing non-PV, while Iso 
PV triggers.  
While trigger sites disclosed by Iso challenge showed excellent correlation with the long- 
term response to PVI (no recurrence in case of PV triggers and recurrence in the single case of 
non-PV trigger), there was no such correlation seen with Ado, PVI being equally effective in 
those with PV or non-PV triggers induced by this drug. 
 
Comparison with previous studies 
The use of Iso in the electrophysiology lab to study triggers of AF is well established (12, 13). 
It has been shown to effectively identify arrhythmogenic PVs that can selectively be ablated, 
achieving similar success to empirical 4-PV isolation (112). On the other hand, Ado has 
mostly been used anecdotally for AF induction. A number of case reports have been 
published of triggers identified with Ado or ATP, most of which originated outside the PVs 
(113-118). More investigators have used ATP to test for non-PV triggers after PVI (119-121). 
Strikingly most of these studies originate from Asia, utilize ATP, and report a high rate of 
non-PV triggers (122). 
Tao et al. (123) used adenosine-triphosphate (ATP) 20 mg for induction in patients with 
paroxysmal or persistent AF. They found that ATP induced AF in 30% of the cases and 
trigger sites were from the PVs in more than 80% of these. The higher rate of PV-triggering 
with ATP compared with our results with Ado may be explained by differences in the mode 
of action and relative doses of the two drugs. The molecular weight of ATP is approximately 
twice that of Ado; therefore, the number of adenosine molecules in 20 mg ATP is much less 
than in 18 mg of Ado, the lower dose in our study.  
On the other hand, ATP exerts a much more pronounced negative chrono- and dromotropic 
response due to its action on P2 receptors located in the left ventricle inducing a cardiocardiac 
vagal reflex (124). The higher relative dose and exclusive action on adenosine (P1) receptors 
may explain the higher rate of RA triggers we saw with Ado. 
Nevertheless, another report from Japan using ATP showed a higher rate of RA triggers. 
Hasebe et al. (125) also used 20 mg of ATP after other methods of AF induction, including 
Iso, failed. More patients had RA triggers than PV triggers with ATP injection (6 vs. 4) and 
frequency analysis suggested the driver to reside in the RA during AF in those with RA 
triggers. These patients were younger and also more often had a family history of AF. The 
authors suggested they may have a distinct form of the arrhythmia, which they named RA 
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fibrillation. However, it is possible that in Hasebe’s study (125), younger patients were more 
difficult to induce with other methods (including Iso) and therefore more likely to receive 
ATP or Ado. The higher rate of RA fibrillation in their case might be merely a manifestation 
of the preferential effect of ATP/Ado on the RA. (125) 
The high percentage of RA triggers seen with Ado/ATP may be related to the drug’s route of 
administration, short half-life and mode of action. Ado/ATP is administered into a central 
vein or directly the RA, and therefore the concentration of the drug is higher in the RA than 
the LA, after having travelled through the lungs, where – due to its very short half-life – a 
great fraction may be eliminated. Moreover, the sensitivity of the RA to Ado is known to be 
higher than the LA (126, 127), explained by an at least two-fold higher expression of the Ado 
receptor in the RA (128). Receptor density in the RA has also been correlated to Ado-induced 
AF in humans (128). Although direct injection of adenosine into the LA had been proposed, 
this was not done in our study, due to concerns of air embolism (129). 
 
Relation between induced and spontaneous triggers 
Few studies have compared induced and spontaneous AF. Lazar et al. analyzed atrial activation 
frequency distribution and found no difference between patients with spontaneous AF (3 
patients) and Iso-induced AF (13 patients) (130), while Calvo et al. showed the same for pacing 
induced AF (131). In the abovementioned study, Tao et al. (123) found that the spontaneous AF 
initiation site was in the PVs in 96% of cases, while after ATP injection in 85%.  
Only in one of the 4 patients with a non-PV trigger manifested by ATP was there a correlation 
with the spontaneous site. In other words, they show - similarly to our results - more non-PV 
triggers with ATP, compared with spontaneous AF, but the majority of those ATP-induced 
non-PV triggers were not clinical. We have seen 4 patients in whom Ado reproduced 
spontaneous AF, but none originated outside the PVs. Therefore, it seems that Ado/ATP may 
reproduce PV-triggers; however, the frequent non-PV triggers seen with these drugs cannot 
be correlated with spontaneous AF. 
The question arises whether non-PV triggers induced by Ado are clinically relevant as initiators 
of spontaneous AF. Triggers of spontaneous AF in our and the above mentioned reports (11, 12, 
111) have been located to the PVs in more than 90% of the cases. The high percentage of non-
PV AF-initiating sites seen with Ado is in sharp contrast with this observation.  
CONCLUSION 
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Atrial fibrillation (AF) is an arrhythmia of increasing prevalence. Catheter ablation is an 
important therapeutic modality for the treatment of patients with AF. Despite a continuous 
improvement in knowledge and technology of PVI is still associated with significant 
recurrence rate especially in persistent AF. Improvement in the outcome of the procedure can 
be expected by influencing the mechanisms leading to persistence of AF, like 
mechanoelectric feedback.  
Better identification of the structures responsible for arrhythmia initiation and maintenance by 
drug challenge and monitoring for DiFi, meticulous care in isolation of arrhythmogenic PVs, 
as well as ablation of non-PV triggers can also improve therapeutic efficiency.  
However, it should be kept in mind that adenosine is likely to induce non-PV triggers without 
established clinical significance and therefore cannot be recommended for the identification 
of trigger sites to guide catheter ablation of paroxysmal AF. 
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NEW OBSERVATIONS 
 
1. The normal LA can adapt to episodes of acute pressure elevation without a substantial 
change in reservoir function and ERP. On the other hand, patients with AF show an 
exaggerated fall in LA reservoir function in response to pressure rise, with an out of 
proportion increase in wall tension leading to a decline in LA ERP. This mechanoelectric 
feedback likely further promotes the development of AF. 
2. Pulmonary veins with dissociated firing are more likely to have a role as initiators and 
perpetuators of paroxysmal AF. 
3. Adenosine is much more likely, than isoproterenol to induce non-PV triggers, especially 
from the RA. The clinical significance of these foci, however, is questionable therefore it 
cannot be recommended for the identification AF triggers. 
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